StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)

Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%

Castle Biosciences Inc grew revenue 9.8% to $377.13M over the twelve months to Sep 30, 2026. Free cash flow was $3.96M, down 84.4% from a year earlier. At the latest close the market valued the company at $1.03B.

Revenue
$377.13M
+9.8% vs. a year earlier
Operating income
-$28.04M
TTM Q3 2026
Free cash flow
$3.96M
-84.4% vs. a year earlier
EPS, diluted
-$0.77
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$1.03B
P/E ratio
–
Price to sales
2.74
Price to book
2.16
Dividend yield
0.00%
Free cash flow yield
0.38%

Fundamentals

Revenue
$377.13M
Net income
-$23.01M
EPS, diluted
-$0.77
Free cash flow
$3.96M
Book value per share
$15.62
Diluted shares
31M

Trading

Next earnings
Feb 25, 2027 (estimated, after the close)
Previous close
$34.50
Open
$34.50
Day's range
$32.57 – $34.50
Volume
347,754
Average volume (20 days)
434,116
Index membership
Russell 2000, Russell 3000 (since Nov 2019)
Beta (5 years)
1.38
52-week range
$17.72 – $44.28
RSI (14 days)
47.8
Volatility (1 year)
53.8%
Relative volume
0.87×
WACC
11.9%

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodCSTLS&P 500DifferenceCSTL per yearS&P 500 per year
1 month+2.8%-3.0%+5.8 pts
3 months+10.6%-2.8%+13.4 pts
Year to date-13.1%+11.5%−24.6 pts
1 year-1.0%+13.5%−14.4 pts
3 years+90.7%+77.7%+13.0 pts+24.0%+21.1%
5 years-34.6%+72.6%−107.2 pts-8.1%+11.5%

Nine years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Revenue

$377.13M+9.8% YoY

Gross profit

$290.66M+5.8% YoY

Operating income

-$28.04M

Net income

-$23.01M

EPS, diluted

-$0.77

Free cash flow

$3.96M-84.4% YoY
Reported periodTrailing twelve months

Press releases

Releases Castle Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Castle Biosciences

Services-Medical Laboratories

Castle Biosciences is a molecular diagnostics company that develops and provides diagnostic and prognostic tests for dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. Its commercial tests include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, and DecisionDx-UM. These tests analyze patient biology using multi-analyte assays, proprietary algorithms, and gene expression profiling to provide clinically actionable data that assists in diagnosing diseases, predicting recurrence or metastasis, and guiding treatment pathways. The company’s customers are healthcare providers and clinicians who order tests to guide patient management.

Company profile, executives and history

Castle Biosciences stock: common questions

What is Castle Biosciences's stock price?

CSTL closed at $33.79 on Nov 13, 2026, down 2.06% on the day. Over the past 52 weeks it traded between $17.72 and $44.28.

What is Castle Biosciences's market cap?

Castle Biosciences was worth $1.03B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is CSTL's P/E ratio?

Castle Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.

How much revenue does Castle Biosciences make?

Castle Biosciences reported revenue of $377.13M for the twelve months to Sep 30, 2026, up 9.8% from a year earlier.

Does Castle Biosciences pay a dividend?

No. Castle Biosciences has not paid a cash dividend over the last twelve months.

When does Castle Biosciences report earnings next?

Castle Biosciences is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has CSTL stock performed over the past year?

Including dividends, CSTL returned -1.0% over the past year, against +13.5% for the S&P 500.

How many CSTL shares are sold short?

2M shares were sold short at the latest FINRA report, 7.03% of the float, or 6.1 days of average trading volume.

Who are Castle Biosciences's competitors?

Companies most similar to Castle Biosciences by business, industry and size include VCYT, FLGT, BLLN, BNR, BDSX.

See a number that looks wrong?